Claims for Patent: 10,442,862

Summary for Patent: 10,442,862

Title:	Use of EGFR biomarkers for the treatment of gastric cancer with anti-EGFR agents
Abstract:	The present invention relates to methods for treating gastric neoplasias, in particular treating patients who have been previously determined to have an EGFR biomarker. Gastric carcinoma (GC) is one of the most common and deadest cancers with -1 million diagnoses and -0.7 million deaths each year worldwide, with high incidence in Eastern Asia.
Inventor(s):	Yang; Jie (Changping, CN), Chen; Yiyou (San Jose, CA), Li; Henry Qixiang (Carlsbad, CA), Cai; Jie (Changping, CN)
Assignee:	Crown Bioscience, Inc. (Taicang) (Jiangsu Province, CN)
Application Number:	14/775,117
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,442,862
Patent Claims:	1. A method for treating gastric neoplasia consisting of administering to a patient in need of such treatment an effective amount of cetuximab, wherein the patient has been determined to have an EGFR gene copy number biomarker in a tumor tissue obtained from the patient before the treatment, and wherein the patient is expected to be more responsive to the treatment compared to patients not having the EGFR gene copy number biomarker, wherein the EGFR gene copy number biomarker is selected from the group consisting of (1) an EGFR gene copy number of at least 7 as determined by Affymetrix genome-wide human SNP6.0 array and PICNIC (Predicting Integral Copy Numbers In Cancer) algorithm, (2) an EGFR gene copy number of at least 4 as determined by realtime quantitative PCR, and (3) an EGFR gene copy number of at least 2.8 as determined by fluorescence in situ hybridization (FISH). 2. The method of claim 1, wherein the gastric neoplasia is gastric adenocarcinoma. 3. A method for treating gastric neoplasia consisting of administering to a patient in need of such treatment an effective amount of cetuximab, wherein the patient has been determined to have an EGFR overexpression biomarker in a tumor tissue obtained from the patient before the treatment, wherein the patient is expected to be more responsive to the treatment compared to patients not having the EGFR overexpression biomarker, wherein the EGFR overexpression biomarker is selected from the group consisting of (1) an EGFR mRNA level of at least 5.0 as measured by Affymetrix GeneChip HG-U219, (2) a relative EGFR gene expression level of at least 0.5 as measured by quantitative RT-PCR, and (3) an EGFR protein level of at least 3 as measured by immunohistorchemical (IHC) analysis. 4. The method of claim 1, wherein the EGFR gene copy number is determined by a hybridization assay. 5. The method of claim 3, wherein the patient has been determined not to have a HER2 biomarker. 6. The method of claim 1, wherein the patient has been determined not to have a HER2 biomarker. 7. The method of claim 1, wherein the tumor tissue is a tissue extract sample or a biopsy sample. 8. The method of claim 3, wherein the tumor tissue is a tissue extract sample or a biopsy sample.

Details for Patent 10,442,862

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004		2033-03-14
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007		2033-03-14